Management of Borderline Resectable Pancreatic Cancer

Seminars in Radiation Oncology

Volumn 24, Issue 2, 2014, Pages 105-112

  Katz, Matthew H G ^a   Crane, Christopher H ^a   Varadhachary, Gauri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BILIARY TRACT DRAINAGE; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LAPAROSCOPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; PANCREAS CANCER; PATIENT CARE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TUMOR BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; MULTIMODALITY CANCER THERAPY; PANCREAS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PROCEDURES; RADIOGRAPHY; SURGERY;

COMBINED MODALITY THERAPY; HUMANS; PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895889311     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.11.006     Document Type: Review

References (43)

1. Katz M.H., Wang H., Fleming J.B., et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009, 16:836-847.
2. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006, 10:1199-1210. [discussion 1210-1191].
3. Neoptolemos J.P., Stocken D.D., Dunn J.A., et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001, 234:758-768.
4. Katz M.H., Marsh R., Herman J.M., et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013, 20:2787-2795.
5. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13:1035-1046.
6. Mollberg N., Rahbari N.N., Koch M., et al. Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis. Ann Surg 2011, 254:882-893.
7. Katz M.H., Lee J.E., Pisters P.W., et al. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: Operative principles and techniques. J Am Coll Surg 2012, 215:e11-e18.
8. Pappas S.G., Christians K.K., Tolat P.P., et al. Staging Chest Computed Tomography and Positron Emission Tomography in Patients With Pancreatic Adenocarcinoma: Utility or Futility? 2013, HPB, Oxford, UK.
9. Satoi S., Yanagimoto H., Toyokawa H., et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 2011, 40:426-432.
10. Contreras C.M., Stanelle E.J., Mansour J., et al. Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol 2009, 100:663-669.
11. Callery M.P., Chang K.J., Fishman E.K., et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009, 16:1727-1733.
12. Yamada S., Fujii T., Sugimoto H., et al. Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of National Comprehensive Cancer Network guidelines. Pancreas 2013, 42:1004-1010.
13. Munroe C.A., Fehmi S.M., Savides T.J. Endoscopic ultrasound in the diagnosis of pancreatic cancer. Expert Opin Med Diagn 2013, 7:25-35.
14. Kosugi C., Furuse J., Ishii H., et al. Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: Clinical and pathologic characteristics and the treatment of needle tract implantation. World J Surg 2004, 28:29-32.
15. Ryozawa S., Iwano H., Taba K., et al. Genetic diagnosis of pancreatic cancer using specimens obtained by EUS-FNA. Dig Endosc 2011, 23(suppl 1):43-45.
16. Xu K., Zhou L., Liang B., et al. Safety and accuracy of percutaneous core needle biopsy in examining pancreatic neoplasms. Pancreas 2012, 41:649-651.
17. Iwashita T., Nakai Y., Samarasena J.B., et al. High single-pass diagnostic yield of a new 25-gauge core biopsy needle for EUS-guided FNA biopsy in solid pancreatic lesions. Gastrointest Endosc 2013, 77:909-915.
18. Aadam A.A., Evans D.B., Khan A., et al. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: A prospective study. Gastrointest Endosc 2012, 76:67-75.
19. Soderlund C., Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: A prospective, randomized, controlled trial. Gastrointest Endosc 2006, 63:986-995.
20. Katz M.H., Pisters P.W., Evans D.B., et al. Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008, 206:833-846. [discussion 846-838].
21. Stokes J.B., Nolan N.J., Stelow E.B., et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011, 18:619-627.
22. Takahashi H., Ohigashi H., Gotoh K., et al. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 2013, 258:1040-1050.
23. Chuong M.D., Springett G.M., Freilich J.M., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biology Phys 2013, 86:516-522.
24. Kim E.J., Ben-Josef E., Herman J.M., et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013, 119:2692-2700.
25. Motoi F., Ishida K., Fujishima F., et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: Results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013, 20:3794-3801.
26. Lee J.L., Kim S.C., Kim J.H., et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012, 152:851-862.
27. Pawlik T.M., Laheru D., Hruban R.H., et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 2008, 15:2081-2088.
28. Birkmeyer J.D., Warshaw A.L., Finlayson S.R., et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999, 126:178-183.
29. Ishikawa O., Ohigashi H., Imaoka S., et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreatoduodenectomy. Arch Surg 1991, 126:885-889.
30. Abrams R.A., Lowy A.M., O'Reilly E.M., et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol 2009, 16:1751-1756.
31. Evans D.B., Varadhachary G.R., Crane C.H., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
32. Varadhachary G.R., Wolff R.A., Crane C.H., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487-3495.
33. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
34. Von Hoff DD, Ervin TJ, Arena FP, et al: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). ASCO Meeting Abstracts 31: LBA148, 2013.
35. Mukherjee S., Hurt C.N., Bridgewater J., et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol 2013, 14:317-326.
36. Katz M.H., Fleming J.B., Bhosale P., et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012, 118:5749-5756.
37. Ben-Josef E., Schipper M., Francis I.R., et al. A Phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 84:1166-1171.
38. Brown M.W., Ning H., Arora B., et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:274-283.
39. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1201.
40. Goitein M. Magical protons?. Int J Radiat Oncol Biol Phys 2008, 70:654-656.
41. Bouchard M., Amos R.A., Briere T.M., et al. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol 2009, 92:238-243.
42. Tzeng C.W., Balachandran A., Ahmad M., et al. Serum Carbohydrate Antigen 19-9 Represents a Marker of Response to Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Cancer 2013, HPB, Oxford, UK, [epub ahead of print].
43. Pancreatic adenocarcinoma Version 2.2012. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) 2012, NCCN, National Comprehensive Cancer Network, Forrt Washington.